[DERM] Dermira, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 30.57 Change: 0.63 (2.1%)
Ext. hours: Change: 0 (0%)

chart DERM

Refresh chart

Strongest Trends Summary For DERM

DERM is in the medium-term up 26% in 2 months and down -37% below S&P in 5 months. In the long-term down -82% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-17.27% ROE-20.31% ROI
Current Ratio10.38 Quick Ratio Long Term Debt/Equity0.02 Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40 K Cash From Investing Activities1.86 M Cash From Operating Activities-5.12 M Gross Profit
Net Profit-14.04 M Operating Profit-14.23 M Total Assets165.61 M Total Current Assets124.49 M
Total Current Liabilities12 M Total Debt1.94 M Total Liabilities24.75 M Total Revenue
Technical Data
High 52 week30.93 Low 52 week6.19 Last close7.28 Last change1.39%
RSI61.43 Average true range0.44 Beta1.02 Volume98.87 K
Simple moving average 20 days6.68% Simple moving average 50 days-13.53% Simple moving average 200 days-26.29%
Performance Data
Performance Week9.64% Performance Month2.25% Performance Quart-43.7% Performance Half-29.66%
Performance Year-73.81% Performance Year-to-date1.25% Volatility daily3.14% Volatility weekly7.02%
Volatility monthly14.38% Volatility yearly49.82% Relative Volume231.19% Average Volume689.88 K
New High New Low

News

2019-03-25 00:00:00 | Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ glycopyrronium Cloth

2019-03-22 16:01:00 | Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-03-20 10:28:02 | Dermira DERM Catches Eye: Stock Jumps 12%

2019-03-19 19:36:06 | Dermira Prices $130.0 Million Public Offering of Common Stock

2019-03-19 16:00:00 | Why Dermira Stock Jumped Again Today

2019-03-19 10:52:02 | Company News For Mar 19, 2019

2019-03-19 08:31:14 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-19 06:06:00 | Can Dermira Stock Keep Soaring?

2019-03-18 16:30:24 | Dermira Announces Proposed Public Offering of Common Stock

2019-03-18 14:22:58 | Why Dermira Stock Is Soaring More than 80% Today

2019-03-18 12:48:21 | Stocks making the biggest moves midday: Facebook, Deutsche Bank, Lumber Liquidators & more

2019-03-18 12:31:42 | Dermira News: Why DERM Stock Is Skyrocketing Today

2019-03-18 12:14:00 | Why Dermira's Shares Are Doubling Today

2019-03-18 11:15:37 | Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop

2019-03-18 10:00:00 | Dermira Shares Rocket After Successful Phase II Eczema Treatment Study

2019-03-18 09:53:04 | Why Dermira Shares Are Shooting Higher After Last Year's Disappointment

2019-03-18 07:24:00 | Dermira shares soar 83% premarket on news of positive trial of dermatitis treatment

2019-03-18 07:00:00 | Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

2019-03-12 10:28:35 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-06 08:05:03 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-05 16:00:00 | Dermira to Present at the Cowen and Company 39th Annual Health Care Conference

2019-03-05 08:03:56 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-03-01 08:51:01 | Implied Volatility Surging for Dermira DERM Stock Options

2019-03-01 08:00:00 | Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate QBREXZA™ glycopyrronium cloth in Patients with Primary Axillary Hyperhidrosis

2019-02-27 03:05:49 | Edited Transcript of DERM earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 16:01:00 | Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

2019-02-26 14:30:00 | Dermira Inc to Host Earnings Call

2019-02-26 08:00:00 | Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting

2019-02-22 08:00:00 | Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ glycopyrronium Cloth in Patients with Primary Palmar Hyperhidrosis

2019-02-21 16:01:00 | Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-19 16:01:00 | Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019

2019-02-12 02:00:00 | Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

2019-02-08 08:07:14 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-02-07 08:02:15 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-02-06 08:07:45 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-02-04 08:02:10 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-29 08:03:13 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-17 08:03:49 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-15 08:03:35 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-09 08:03:56 | See what the IHS Markit Score report has to say about Dermira Inc.

2019-01-08 12:50:13 | At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

2018-12-20 08:04:11 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-12-18 22:28:01 | Do Hedge Funds Love Dermira Inc DERM?

2018-12-17 08:04:24 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-12-11 17:07:35 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-12-05 14:58:37 | Is Dermira Inc’s NASDAQ:DERM CEO Paid At A Competitive Rate?

2018-12-04 07:30:00 | Dermira Enters into Credit Facility with Athyrium Capital Management

2018-11-28 08:40:00 | Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-24 08:03:33 | See what the IHS Markit Score report has to say about Dermira Inc.

2018-11-19 08:00:00 | Dermira to Present at Evercore ISI HealthCONx Conference